Eli Lilly And Co (NYSE:LLY) major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction on Friday, November 16th. The stock was sold at an average price of $113.74, for a total transaction of $22,748,000.00. Following the sale, the insider now directly owns 118,600,804 shares in the company, valued at $13,489,655,446.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Monday, November 19th, Lilly Endowment Inc sold 195,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $115.31, for a total transaction of $22,485,450.00.
  • On Monday, November 12th, Lilly Endowment Inc sold 202,540 shares of Eli Lilly And Co stock. The stock was sold at an average price of $113.48, for a total transaction of $22,984,239.20.
  • On Wednesday, October 17th, Lilly Endowment Inc sold 174,696 shares of Eli Lilly And Co stock. The stock was sold at an average price of $113.25, for a total transaction of $19,784,322.00.
  • On Monday, October 8th, Lilly Endowment Inc sold 14,632 shares of Eli Lilly And Co stock. The stock was sold at an average price of $115.91, for a total transaction of $1,695,995.12.
  • On Wednesday, October 3rd, Lilly Endowment Inc sold 78,962 shares of Eli Lilly And Co stock. The stock was sold at an average price of $109.01, for a total transaction of $8,607,647.62.
  • On Thursday, September 27th, Lilly Endowment Inc sold 92,447 shares of Eli Lilly And Co stock. The stock was sold at an average price of $107.00, for a total transaction of $9,891,829.00.
  • On Tuesday, September 25th, Lilly Endowment Inc sold 55,590 shares of Eli Lilly And Co stock. The stock was sold at an average price of $106.41, for a total transaction of $5,915,331.90.
  • On Friday, September 7th, Lilly Endowment Inc sold 180,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $106.76, for a total transaction of $19,216,800.00.
  • On Thursday, August 30th, Lilly Endowment Inc sold 190,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $105.42, for a total transaction of $20,029,800.00.

Shares of LLY opened at $114.72 on Wednesday. The stock has a market capitalization of $120.58 billion, a PE ratio of 26.80, a P/E/G ratio of 1.78 and a beta of 0.29. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $116.61. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.04. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. During the same period last year, the firm earned $1.05 earnings per share. Eli Lilly And Co’s revenue for the quarter was up 7.1% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly And Co will post 5.58 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be given a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 1.96%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is 52.57%.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Eli Lilly And Co by 0.4% during the third quarter. BlackRock Inc. now owns 66,925,674 shares of the company’s stock worth $7,181,792,000 after acquiring an additional 280,777 shares during the period. Capital International Investors increased its position in Eli Lilly And Co by 7.6% during the third quarter. Capital International Investors now owns 10,237,075 shares of the company’s stock worth $1,098,541,000 after acquiring an additional 722,431 shares during the period. Janus Henderson Group PLC increased its position in Eli Lilly And Co by 7.5% during the second quarter. Janus Henderson Group PLC now owns 10,008,768 shares of the company’s stock worth $854,049,000 after acquiring an additional 700,582 shares during the period. Bank of New York Mellon Corp increased its position in Eli Lilly And Co by 0.3% during the third quarter. Bank of New York Mellon Corp now owns 9,501,142 shares of the company’s stock worth $1,019,568,000 after acquiring an additional 27,009 shares during the period. Finally, FMR LLC increased its position in Eli Lilly And Co by 526.5% during the third quarter. FMR LLC now owns 7,444,216 shares of the company’s stock worth $798,838,000 after acquiring an additional 6,255,915 shares during the period. 76.91% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have issued reports on LLY. TheStreet lowered shares of Eli Lilly And Co from a “b” rating to a “c+” rating in a research report on Friday, August 24th. Bank of America increased their price objective on shares of Eli Lilly And Co from $90.00 to $94.00 and gave the company a “neutral” rating in a research report on Wednesday, July 25th. Cantor Fitzgerald set a $110.00 price objective on shares of Eli Lilly And Co and gave the company a “buy” rating in a research report on Monday, September 17th. ValuEngine raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Finally, Morgan Stanley increased their price objective on shares of Eli Lilly And Co from $93.00 to $102.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 31st. Eight investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Eli Lilly And Co currently has a consensus rating of “Buy” and a consensus price target of $111.19.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/11/21/lilly-endowment-inc-sells-200000-shares-of-eli-lilly-and-co-lly-stock.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: How mutual funds make money

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.